Angela Dascalescu

Dr. Angela Dascalescu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MTMihaela-Madalina Timofte-Zorila
Mihaela-Madalina Timofte-Zorila
MPMariana Pavel-Tanasa
Mariana Pavel-Tanasa
DCDaniela Constantinescu
Daniela Constantinescu
CCCorina Cianga
Corina Cianga
DBDaniel Constantin Branisteanu
Daniel Constantin Branisteanu
Cristina PredaCristina Preda
Cristina Preda
Ocular graft versus host disease (oGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and may be associated with dry eye disease and chronic inflammation and fibrosis. Immune dysregulation, particularly the Th1/Th2 imbalance, plays a key role in the progression of oGVHD. This case study presents two oGVHD patients (a 20-year-old with acute oGVHD and a 59-year-old with chronic oGVHD), analyzing clinical dry eye parameters (Schirmer test I, tear film break-up time, Ocular Surface Disease Index (OSDI), and kerato-conjunctival staining) alongside tear biomarkers. A 27-plex tear cytokine analysis was performed using the Luminex200 platform, assessing various biomarkers against a control group-defined normal range. Key biomarkers included beta2-microglobulin (β2-MG), complement components, chemokines, growth factors, and both pro-inflammatory and anti-inflammatory cytokines, as well a series of soluble ligand and receptors. The study identified distinct biomarker progression patterns during topical corticosteroid treatment in the acute oGHVD patient, suggesting potential shifts in Th1/Th2 responses as the disease progressed. Notably, the soluble CD27, TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2), chemokine ligand 2 (CCL2), and IL-1β, initially elevated, normalized during treatment, while tear-soluble Fas remained highly elevated (>400-fold). Conversely, soluble TRAIL, which was initially at very low levels (100-fold lower), increased during treatment and reached normal tear levels, coinciding with improvements in the clinical ocular inflammation symptoms and OSDI score. This case study also highlights potential differences between acute and chronic oGVHD, particularly in the distinct patterns of novel tear biomarkers such as CD27, TRAIL/TRAIL-R2, and CCL2. Enhancing our understanding of biomarker dynamics may improve disease monitoring and pave the way for personalized management strategies to improve patient outcomes.

19 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CMCosmin Minciuna
Cosmin Minciuna
DMDorina Adelina Minciuna
Dorina Adelina Minciuna
ADAngela Dascalescu
Angela Dascalescu
ATAmalia Titieanu
Amalia Titieanu
VCVlad Andrei Cianga
Vlad Andrei Cianga
LMLucian Miron
Lucian Miron
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous malignancy with variable outcomes. Accurate risk prediction at diagnosis remains essential to guide treatment and follow-up strategies. In this retrospective study we aimed to assess the performance of multiple modeling approaches to predict death by 26 months of follow-up in patients with DLBCL using data available in the diagnostic stage. Methods: In this study we included 412 patients with DLBCL who were evaluated, treated, and followed-up at the Regional Institute of Oncology in Iasi, Romania, between 2015 and 2023. Clinical and paraclinical data determined at baseline examination was used to train and test six machine learning models (logistic regression, random forest—RF, support vector machine with a radial-basis kernel—SVM-RBF, multilayer perceptron neural network—MLP, random survival forest—RSF, and extreme gradient boosting—XGBoost) and to compare their performance to the Cox proportional hazards model. Results: Among the models, RF achieved the highest discrimination (AUC = 0.9060), with balanced performance (accuracy = 0.833; F1 = 0.902), followed by XGBoost (AUC = 0.8335) and MLP (AUC = 0.7861; accuracy = 0.849). RF and logistic regression demonstrated the best calibration (Brier = 0.360 and 0.377). The Cox model achieved moderate discrimination (time-dependent AUC = 0.5561; C-index = 0.55). Conclusions: Our findings align with contemporary reports showing that machine learning frameworks can outperform classical prediction approaches.

30 December 2020 in Archive of Clinical Cases
Verified
Journal Article
Open access
PDF file
VCVlad Andrei Cianga
Vlad Andrei Cianga
CDCătălin Doru Dănăilă
Cătălin Doru Dănăilă
IAIon Antohe
Ion Antohe
RORaluca Oană
Raluca Oană
MMMihaela Mențel
Mihaela Mențel
ADAngela Dascalescu
Angela Dascalescu
Blastic plasmacytoid dendritic cell neoplasms (BPDCNs) are extremely rare and aggressive hematological malignancies that derive from precursors of plasmacytoid dendritic cells (pDC) and frequently involve skin lesions and bone marrow infiltration. They mostly affect the elderly population and the prognosis is poor with the therapeutic choices currently available. Diagnosis is made with the help of tools such as immuno-histochemistry and flow cytometry. Here, we present a particular case of BPDCN with a positive FLT3-D835 mutation and we discuss the possible impact this may have on the evolution of the disease and response to treatment.

18 August 2023 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
ATAmalia-Andrea Titieanu
Amalia-Andrea Titieanu
VCVlad Andrei Cianga
Vlad Andrei Cianga
CDCatalin Doru Danaila
Catalin Doru Danaila
MDMIHAIELA LOREDANA DRAGOȘ
MIHAIELA LOREDANA DRAGOȘ
ICIVANOV IULIU CRISTIAN
IVANOV IULIU CRISTIAN
ADAngela Dascalescu
Angela Dascalescu

24 March 2025 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
DFDiana-Marina Fortoes
Diana-Marina Fortoes
ENElena Nicorici
Elena Nicorici
CMCosmin Minciuna
Cosmin Minciuna
VCVlad Andrei Cianga
Vlad Andrei Cianga
RTRamona Timofte
Ramona Timofte
CDCatalin Danaila
Catalin Danaila
Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma. Methods: Retrospective single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2017–2021 (immunotherapy), with survival endpoints (OS, PFS, EFS1-3) analyzed by Kaplan–Meier and log-rank tests. Results: The immunotherapy group achieved a higher overall response rate (80% vs. 36.7%, p=0.001), longer median OS (47 vs. 30 months) and superior EFS1–3 (33 vs. 16 months, 32.5 vs. 8 months, 38 vs. 23 months; all p 0.05) compared to historical controls. Conclusion: Incorporation of brentuximab vedotin and PD-1 blockade before and after autologous SCT significantly improves response and survival outcomes in relapsed/refractory Hodgkin lymphoma, supporting earlier use of these agents in salvage and frontline settings.

Verified
Journal Article
Open access
PDF file
CMCosmin Minciuna
Cosmin Minciuna
DMDorina Adelina Minciuna
Dorina Adelina Minciuna
ADAngela Dascalescu
Angela Dascalescu
ATAmalia Titieanu
Amalia Titieanu
VCVlad Andrei Cianga
Vlad Andrei Cianga
LMLucian Miron
Lucian Miron
Background/Objectives: Central Nervous System (CNS) relapse represents a severe and often fatal complication of Diffuse Large B-Cell Lymphoma (DLBCL). This study aimed to evaluate clinical, biological, and treatment-related factors associated with progression-free survival (PFS) until CNS relapse in patients with DLBCL. Methods: A retrospective cohort study was conducted using clinical data from adult DLBCL patients evaluated and treated at the Regional Institute of Oncology, Iași, Romania, between 2015 and 2023. Associations between clinical, biological, and treatment-related variables and CNS relapse were evaluated using univariate and multivariable Cox proportional hazards models, Fine–Gray competing-risk analyses, and propensity score-based methods to address confounding by indication for CNS prophylaxis. Results: Twenty-six CNS relapse events (6.3%) and 72 deaths without prior CNS relapse occurred over a median follow-up of 12 months. In the prespecified reduced multivariable Cox model, non-R-CHOP regimens (HR 4.57, 95% CI 1.67–12.52; p = 0.003) and high CNS-IPI scores (HR 4.70, 95% CI 1.14–19.46; p = 0.033) were independently associated with CNS relapse. The 20-month cumulative incidence of CNS relapse was 7.0% in the R-CHOP-like group versus 35.2% in the non-R-CHOP group (Gray’s test p < 0.001). Fine–Gray modeling confirmed the association for non-R-CHOP regimens (SHR 3.38, 95% CI 1.21–9.45; p = 0.02). Cell-of-origin subtype, double-expressor phenotype, and Ki-67 were not significantly associated with CNS relapse. Conclusions: High CNS-IPI and treatment with non-R-CHOP regimens independently predicted earlier CNS relapse. Future multicenter studies with molecular profiling are needed to refine CNS risk stratification.